FDA Approves Genvoya, New Four-in-One Pill For HIV

Posted: Nov 7 2015, 6:22am CST | by , Updated: Nov 7 2015, 11:20pm CST, in News | Latest Science News


FDA Approves Genvoya,  New Four-in-One Pill for HIV

The all in one pill is a new version of the drug Tenofovir which reduces side effects of other HIV drugs.

Today FDA announced it has approved a new pill for HIV treatment. The all in one pill is a new version of the drug Tenofovir. The drug was previously used in reducing the side effects from all the other drugs taken in the HIV regime.

The U.S. Food and Drug Administration approved the new pill called Genvoya. Genvoya contains doses of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. The pill is liable for consumption for patients above 12 years of age.

The patients also needs to weigh at least 77 pounds for the pill consumption. The patients also need to have no prior history of treatment for HIV. The pill is also believed to result in less kidney toxicity and fewer reductions in bone density. Other pills containing Tenofovir for HIV have multiple side effects.

HIV treatments usually result in low bone mineral density and renal impairment. The side effects are a problem since the HIV population is on the rise. The problems occur due to the combination of HIV infection and antiretroviral treatments. The natural aging process also aids in the complications. 

The pill is being developed by Gilead Sciences a California-based company. The pill underwent four clinical trials with 3,171 participants. The pill was tested in 21 countries with a wide variety of patients.

The pill was found to be effective at lowering viral loads along with less kidney toxicity and fewer decreases in bone density. The pill Genvoya was also compared to another HIV drug Stribild and came out as more efficient. 

“As the HIV patient population ages there is an increased risk for development of age- and treatment-related comorbidities, including low bone mineral density and renal impairment. This is due to the combination of HIV infection, antiretroviral treatments and the natural aging process,” said David Wohl, MD, Associate Professor of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill and lead author of the Genvoya efficacy analysis.

“Given its demonstrated efficacy and safety profile, Genvoya represents an important new treatment option for a range of patients who are either new to therapy or who choose to switch treatments.” 

You May Like


The Author

<a href="/latest_stories/all/all/20" rel="author">Sumayah Aamir</a>
Sumayah Aamir (Google+) has deep experience in analyzing the latest trends.




Leave a Comment

Share this Story

Follow Us
Follow I4U News on Twitter
Follow I4U News on Facebook

Read the Latest from I4U News